Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group

Ryan D. Roberts, Michael M. Lizardo, Damon R. Reed, Pooja Hingorani, Jason Glover, Wendy Allen-Rhoades, Timothy Fan, Chand Khanna, E. Alejandro Sweet-Cordero, Thomas Cash, Michael W. Bishop, Meenakshi Hegde, Aparna R. Sertil, Christian Koelsche, Lisa Mirabello, David Malkin, Poul H. Sorensen, Paul S. Meltzer, Katherine A. Janeway, Richard GorlickBrian D. Crompton

Research output: Contribution to journalReview article

Abstract

Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.

Original languageEnglish (US)
Pages (from-to)3514-3525
Number of pages12
JournalCancer
Volume125
Issue number20
DOIs
StatePublished - Oct 15 2019

Fingerprint

Osteosarcoma
Poisons
Research
Epigenomics
Lung Diseases
Neoplasms
Carcinogenesis
Research Personnel
Clinical Trials
Organizations
Neoplasm Metastasis
Bone and Bones
Mutation
Therapeutics

Keywords

  • osteosarcoma
  • pediatric oncology
  • program development
  • sarcoma
  • translational biology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Roberts, R. D., Lizardo, M. M., Reed, D. R., Hingorani, P., Glover, J., Allen-Rhoades, W., ... Crompton, B. D. (2019). Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer, 125(20), 3514-3525. https://doi.org/10.1002/cncr.32351

Provocative questions in osteosarcoma basic and translational biology : A report from the Children's Oncology Group. / Roberts, Ryan D.; Lizardo, Michael M.; Reed, Damon R.; Hingorani, Pooja; Glover, Jason; Allen-Rhoades, Wendy; Fan, Timothy; Khanna, Chand; Sweet-Cordero, E. Alejandro; Cash, Thomas; Bishop, Michael W.; Hegde, Meenakshi; Sertil, Aparna R.; Koelsche, Christian; Mirabello, Lisa; Malkin, David; Sorensen, Poul H.; Meltzer, Paul S.; Janeway, Katherine A.; Gorlick, Richard; Crompton, Brian D.

In: Cancer, Vol. 125, No. 20, 15.10.2019, p. 3514-3525.

Research output: Contribution to journalReview article

Roberts, RD, Lizardo, MM, Reed, DR, Hingorani, P, Glover, J, Allen-Rhoades, W, Fan, T, Khanna, C, Sweet-Cordero, EA, Cash, T, Bishop, MW, Hegde, M, Sertil, AR, Koelsche, C, Mirabello, L, Malkin, D, Sorensen, PH, Meltzer, PS, Janeway, KA, Gorlick, R & Crompton, BD 2019, 'Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group', Cancer, vol. 125, no. 20, pp. 3514-3525. https://doi.org/10.1002/cncr.32351
Roberts RD, Lizardo MM, Reed DR, Hingorani P, Glover J, Allen-Rhoades W et al. Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 2019 Oct 15;125(20):3514-3525. https://doi.org/10.1002/cncr.32351
Roberts, Ryan D. ; Lizardo, Michael M. ; Reed, Damon R. ; Hingorani, Pooja ; Glover, Jason ; Allen-Rhoades, Wendy ; Fan, Timothy ; Khanna, Chand ; Sweet-Cordero, E. Alejandro ; Cash, Thomas ; Bishop, Michael W. ; Hegde, Meenakshi ; Sertil, Aparna R. ; Koelsche, Christian ; Mirabello, Lisa ; Malkin, David ; Sorensen, Poul H. ; Meltzer, Paul S. ; Janeway, Katherine A. ; Gorlick, Richard ; Crompton, Brian D. / Provocative questions in osteosarcoma basic and translational biology : A report from the Children's Oncology Group. In: Cancer. 2019 ; Vol. 125, No. 20. pp. 3514-3525.
@article{ccabfebe3824420bbf5c78f3eef1b7f8,
title = "Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group",
abstract = "Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.",
keywords = "osteosarcoma, pediatric oncology, program development, sarcoma, translational biology",
author = "Roberts, {Ryan D.} and Lizardo, {Michael M.} and Reed, {Damon R.} and Pooja Hingorani and Jason Glover and Wendy Allen-Rhoades and Timothy Fan and Chand Khanna and Sweet-Cordero, {E. Alejandro} and Thomas Cash and Bishop, {Michael W.} and Meenakshi Hegde and Sertil, {Aparna R.} and Christian Koelsche and Lisa Mirabello and David Malkin and Sorensen, {Poul H.} and Meltzer, {Paul S.} and Janeway, {Katherine A.} and Richard Gorlick and Crompton, {Brian D.}",
year = "2019",
month = "10",
day = "15",
doi = "10.1002/cncr.32351",
language = "English (US)",
volume = "125",
pages = "3514--3525",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "20",

}

TY - JOUR

T1 - Provocative questions in osteosarcoma basic and translational biology

T2 - A report from the Children's Oncology Group

AU - Roberts, Ryan D.

AU - Lizardo, Michael M.

AU - Reed, Damon R.

AU - Hingorani, Pooja

AU - Glover, Jason

AU - Allen-Rhoades, Wendy

AU - Fan, Timothy

AU - Khanna, Chand

AU - Sweet-Cordero, E. Alejandro

AU - Cash, Thomas

AU - Bishop, Michael W.

AU - Hegde, Meenakshi

AU - Sertil, Aparna R.

AU - Koelsche, Christian

AU - Mirabello, Lisa

AU - Malkin, David

AU - Sorensen, Poul H.

AU - Meltzer, Paul S.

AU - Janeway, Katherine A.

AU - Gorlick, Richard

AU - Crompton, Brian D.

PY - 2019/10/15

Y1 - 2019/10/15

N2 - Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.

AB - Patients who are diagnosed with osteosarcoma (OS) today receive the same therapy that patients have received over the last 4 decades. Extensive efforts to identify more effective or less toxic regimens have proved disappointing. As we enter a postgenomic era in which we now recognize OS not as a cancer of mutations but as one defined by p53 loss, chromosomal complexity, copy number alteration, and profound heterogeneity, emerging threads of discovery leave many hopeful that an improving understanding of biology will drive discoveries that improve clinical care. Under the organization of the Bone Tumor Biology Committee of the Children's Oncology Group, a team of clinicians and scientists sought to define the state of the science and to identify questions that, if answered, have the greatest potential to drive fundamental clinical advances. Having discussed these questions in a series of meetings, each led by invited experts, we distilled these conversations into a series of seven Provocative Questions. These include questions about the molecular events that trigger oncogenesis, the genomic and epigenomic drivers of disease, the biology of lung metastasis, research models that best predict clinical outcomes, and processes for translating findings into clinical trials. Here, we briefly present each Provocative Question, review the current scientific evidence, note the immediate opportunities, and speculate on the impact that answered questions might have on the field. We do so with an intent to provide a framework around which investigators can build programs and collaborations to tackle the hardest problems and to establish research priorities for those developing policies and providing funding.

KW - osteosarcoma

KW - pediatric oncology

KW - program development

KW - sarcoma

KW - translational biology

UR - http://www.scopus.com/inward/record.url?scp=85070889027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070889027&partnerID=8YFLogxK

U2 - 10.1002/cncr.32351

DO - 10.1002/cncr.32351

M3 - Review article

C2 - 31355930

AN - SCOPUS:85070889027

VL - 125

SP - 3514

EP - 3525

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 20

ER -